ROR1 Targeting with the Antibody Drug-Conjugate VLS-101 in Aggressive Non-Hodgkins Lymphoma

Time: 1:30 pm
day: Track A - Day 1 PM


  • ROR1 is an onco-embryonic cell surface receptor with expression in various cancers
  • The novel antibody-drug conjugate VLS-101 demonstrates promising in vivo activity in preclinical Lynphoma models
  • Confirm ROR1 as a target and demonstrate the therapeutic potential of using an ADC directed toward ROR1 for the treatment of hematological cancers